griffonilide

CAS No. 61371-55-9

griffonilide ( —— )

Catalog No. M18901 CAS No. 61371-55-9

Griffonilide is an extract from the Semiaquilegia adoxoides root, a traditional anticancer herb.

Purity : 98%

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 101 In Stock
10MG 149 In Stock
25MG 249 In Stock
50MG 357 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    griffonilide
  • Note
    Research use only, not for human use.
  • Brief Description
    Griffonilide is an extract from the Semiaquilegia adoxoides root, a traditional anticancer herb.
  • Description
    Griffonilide is an extract from the Semiaquilegia adoxoides root, a traditional anticancer herb.
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    61371-55-9
  • Formula Weight
    168.15
  • Molecular Formula
    C8H8O4
  • Purity
    98%
  • Solubility
    ——
  • SMILES
    O1C(=O)C=C2[C@H]1[C@H]([C@@H](C=C2)O)O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Chingwaru W,et al. Therapeutic and Prophylactic Potential of Morama (Tylosema esculentum): A Review. Phytother Res. 2015 Oct;29(10):1423-38.
molnova catalog
related products
  • 5-Hydroxy-7-(4-hydro...

    5-Hydroxy-7-(4'-hydroxy-3'-methoxyphenyl)-1-phenyl-3-heptanone (DHPA) is a pancreatic lipase inhibitor, it shows antihyperlipidemic activity.

  • Hexa-D-arginine

    Hexa-D-arginine?is an inhibitor of furinblocks the activation of Pseudomonas aeruginosa exotoxin A in vivo.

  • Remimazolam

    Remimazolam is a benzodiazepine derivative drug as an alternative to the short-acting imidazobenzodiazepine midazolam, for use in induction of anaesthesia and conscious sedation for minor invasive procedures.?Remimazolam was found to be both faster acting and shorter lasting than midazolam, and human clinical trials showed a faster recovery time and predictable, consistent pharmacokinetics, suggesting some advantages over existing drugs for these applications.?